CJC-1295 dosage calculator: how to actually work out a dose

Last updated 2026-07-26

Is there a real, validated CJC-1295 dosage calculator?

No. There is no CJC-1295 dosage calculator backed by the FDA, a peer-reviewed dosing trial, or a manufacturer package insert, because CJC-1295 has no FDA-approved human indication at all ^[1]. The compound is sold in the United States almost exclusively as a research chemical, labeled "not for human consumption," through research supply channels ^[2]. That matters more than it sounds like it should. A real dosage calculator (the kind you'd trust for, say, insulin or warfarin) is built from pharmacokinetic and pharmacodynamic data collected across hundreds or thousands of human subjects, with dose-response curves, half-life measurements, and safety margins established in controlled trials. CJC-1295 has none of that at the scale needed. The human data that does exist comes from a small number of published pharmacology studies, mostly from the mid-2000s, and none of them were designed to answer "what dose should a person self-administer for a chosen goal." So what you'll find online calling itself a calculator is really just a unit converter dressed up: it takes a vial concentration, a target mcg or mg dose, and spits out an injection volume in units on an insulin syringe. That's genuinely useful (we'll build you the math below), but it is not the same thing as a validated dosage recommendation. Anyone implying otherwise is selling you confidence that doesn't exist yet. For a full walkthrough of the reasoning behind common protocol numbers, see our CJC-1295 dosage guide, which goes deeper into the rationale than a calculator alone can.

What dose of CJC-1295 do research protocols actually use?

Published pharmacology work on CJC-1295 (without DAC, the original short-acting molecule sometimes called mod GRF or GRF(1-29)) used doses in the range of roughly 1 to 2 mcg/kg of body weight in single-dose human pharmacokinetic studies ^[3]. For a 70 kg (154 lb) adult, that lands around 70 to 140 mcg per dose in the studies that exist. Bodybuilding and longevity-forum protocols, by contrast, usually recommend flat doses of 100 mcg to 300 mcg per injection, once or twice daily, unrelated to body weight ^[4]. That range didn't come from a dose-finding trial. It came from informal trial-and-error shared across forums over roughly fifteen years, converging on numbers that "feel" tolerable rather than numbers shown to optimize a measured outcome. That's a meaningful distinction to sit with: a number repeated a thousand times on a forum is not the same as a number replicated in a lab. Here's a rough comparison of where the numbers come from: | Source | Typical CJC-1295 (no-DAC) dose | Basis |

How do I calculate CJC-1295 dosage from vial concentration and syringe units?

This is the part a calculator actually helps with: converting a chosen dose (say 100 mcg) into a volume you can measure on an insulin syringe, given how the peptide was reconstituted. The formula is simple. Concentration (mcg per mL) equals total peptide in the vial (mcg) divided by the mL of bacteriostatic water added. Then, dose volume (mL) equals your target dose (mcg) divided by that concentration. Insulin syringes are usually marked in units, where 100 units equals 1 mL (a "U-100" syringe), so you multiply the mL figure by 100 to get syringe units. Worked example: a 2 mg (2,000 mcg) vial of CJC-1295, reconstituted with 2 mL of bacteriostatic water, gives a concentration of 1,000 mcg/mL. A 100 mcg dose is 0.1 mL, which is 10 units on a U-100 insulin syringe. Second example: the same 2 mg vial reconstituted with 5 mL instead gives 400 mcg/mL. That same 100 mcg dose is now 0.25 mL, or 25 units. Reconstitution volume changes the syringe reading a lot, so "units" alone means nothing without knowing how the vial was mixed. This is exactly where people make math errors and end up over- or under-dosing by a wide margin, and it's the single best argument for double-checking any number a calculator gives you by hand, with the formula above, before drawing anything into a syringe. We don't publish an interactive tool here because a static formula, done carefully, is safer than an unverified web widget doing hidden math you can't inspect.

What's the difference between CJC-1295 and CJC-1295 with DAC, and does it change the dose?

Yes, substantially, and this is the single most important distinction in any CJC-1295 dosing discussion. CJC-1295 without DAC is chemically closer to the natural growth-hormone-releasing hormone fragment and has a short half-life, on the order of tens of minutes in circulation ^[3]. CJC-1295 with DAC (Drug Affinity Complex) has a fatty-acid modification that lets it bind reversibly to albumin in the blood, extending its half-life to roughly 6 to 8 days, based on the original pharmacology publication describing the modification ^[5]. That half-life difference drives completely different dosing patterns. No-DAC versions are typically dosed multiple times per day or day-around-injection because they clear fast and are meant to mimic natural GHRH pulses. DAC versions are dosed roughly once weekly precisely because they stay active for days, so daily dosing would just stack the drug rather than mimic pulsatility. Mixing up the two in a calculator is a real, common mistake. Someone using a no-DAC-style calculator (100 to 300 mcg, once or twice daily) but injecting the DAC version can end up dosing 7 to 14 times too frequently relative to what the extended half-life would call for. Conversely, using once-weekly DAC-style logic on a no-DAC product would badly under-dose the growth hormone pulse pattern the peptide is meant to support. If you're specifically working with the DAC version, use our dedicated CJC-1295 DAC dosage calculator guide instead of applying no-DAC math to it. For the fuller mechanistic comparison, see CJC-1295 with DAC.

Why is CJC-1295 usually paired with ipamorelin, and does that change the dosage math?

CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue: it works on the GHRH receptor in the pituitary. Ipamorelin is a ghrelin-receptor agonist, a different mechanism entirely, sometimes grouped under "growth hormone secretagogues" or GHRPs ^[6]. The rationale researchers give for combining them is that GHRH and ghrelin-mimetic signaling act on different receptors but converge on growth hormone release, so stacking them may produce a larger pulse than either alone, an idea with some support in older combined-secretagogue pharmacology literature ^[7]. That's a mechanistic rationale, not a clinical outcome demonstrated for the CJC-1295/ipamorelin pair specifically in a controlled human trial with meaningful sample size. Be honest with yourself about that gap. Older studies combining a GHRH analogue with a separate ghrelin-mimetic did show augmented GH release compared to either compound alone in some settings ^[7], but that is different from a study showing the specific combination, at self-administered research-chemical doses, produces a defined clinical benefit in healthy adults. For dosing math, the two peptides are typically calculated independently and drawn separately (or combined in the same syringe after separate reconstitution math), because ipamorelin's typical range (roughly 200 to 300 mcg per dose in most informal protocols) doesn't scale off CJC-1295's dose at all. Treat them as two separate calculator problems, not one combined ratio.

How does body weight factor into a CJC-1295 dose?

In the human pharmacology studies that exist, dosing was calculated on a mcg/kg basis, which is standard practice for early-phase peptide pharmacology because it accounts for differences in distribution volume and clearance across body sizes ^[3]. A 1.5 mcg/kg dose is about 105 mcg for a 70 kg adult and about 150 mcg for a 100 kg adult. Most popular flat-dose protocols ignore this scaling entirely and just say "100 mcg" regardless of whether the person weighs 55 kg or 110 kg. If you're going to use body weight in your own math, mcg/kg is the more defensible approach because it at least echoes how the studies were structured, even though the studies themselves were small, short, and not designed to define an optimal dose for any particular goal. Don't confuse using a study-consistent method with the method having been validated for your actual use case.

How often should CJC-1295 be dosed, and does frequency belong in the calculator?

Yes, frequency is arguably more consequential than the absolute mcg number, because it interacts with half-life. No-DAC CJC-1295 clears within roughly an hour or two, so its use is built around timing (commonly before bed or before a fasted training session) rather than maintaining a steady blood level, which mirrors how the body naturally pulses growth hormone release rather than keeping it constant ^[3]. DAC CJC-1295's multi-day half-life means once-weekly dosing keeps drug present continuously, closer to a low steady-state elevation than a pulse. Some researchers and forum protocols alternate DAC with no-DAC compounds to try to get both a sustained baseline and daily pulses, but there's no controlled trial validating that combined schedule works better than either alone. It is a plausible-sounding regimen built on plausible-sounding pharmacology, not a demonstrated one.

What happens if I get the CJC-1295 dosage calculation wrong?

The realistic risk profile here isn't like getting a blood-thinner dose wrong, but it isn't nothing either. Reported effects associated with GH-secretagogue use, drawn from case reports and adjacent GH-axis pharmacology, include water retention, joint or nerve-related discomfort, flushing at the injection site, and effects on blood glucose or insulin sensitivity from elevated GH-axis activity . Because CJC-1295 lacks large controlled safety trials, dose-response for adverse effects at the higher end of self-administered ranges isn't well mapped, which is itself a reason to stay conservative. A math error in reconstitution (see the worked example above) is probably the most common real-world mistake, more common than picking a "wrong" mcg target. Under-dosing from a math slip mostly wastes product. Over-dosing by a large factor (say, injecting 10x intended volume because bacteriostatic water volume was miscounted) is the scenario worth being genuinely careful about, and it's avoidable with the simple concentration formula covered earlier in this piece, checked twice, every time you draw up a new vial. For a full rundown of documented and reported effects, read CJC-1295 side effects.

Where does the underlying research on CJC-1295 come from?

The core human pharmacology data traces back to work originally developed under Conjuchem Biotechnologies, which studied the DAC modification and its extended half-life in the mid-2000s, published in peer-reviewed pharmacology literature ^[5]. CJC-1295 has never completed FDA approval as a drug for any indication, and it is not sold as an approved medication in the United States; it exists commercially almost entirely in the research-chemical and compounding-adjacent gray zone, a status confirmed by its absence from the FDA's approved drug database ^[1]. That's worth sitting with before trusting any calculator, blog, or forum thread that presents dosing numbers with more confidence than the underlying evidence supports. The honest state of the evidence is: some solid early pharmacokinetic characterization, a handful of small mechanistic studies, and a large volume of anecdotal protocol-sharing that fills the gaps with numbers nobody tested at scale. For the fuller evidence review, read our CJC-1295 hub article, which lays out what's actually been studied versus what's assumed.

So what should I actually do instead of trusting an online calculator?

Do the reconstitution math yourself, by hand, every single time, using the formula in this article. Don't rely on a black-box widget you can't audit, especially for something you're about to inject. If you're weighing whether to use a research protocol at all, start by reading the dosing and safety literature honestly rather than looking for a number to plug in. Our CJC-1295 dosage article covers the reasoning in more depth, and CJC-1295 side effects covers what's actually been reported. If you're at the point of sourcing, the quality and traceability of the product matters as much as the dose you calculate for it, since a mislabeled concentration makes every calculation above meaningless. CJC-1295 Co reviews providers against that traceability standard and can point you toward a provider-reviewed route, with the order fulfilled through a named, verified pharmacy partner rather than an anonymous vial, if that's the path you're considering. See CJC-1295 for sale for that comparison.

Frequently asked questions

Is there an official CJC-1295 dosage calculator?

No. No FDA-approved or clinically validated calculator exists, because CJC-1295 has no approved human indication and no large-scale dosing trial. Tools calling themselves "calculators" online are unit converters (mcg to mL to syringe units) based on vial concentration math, not validated medical dosing recommendations.

How do I calculate CJC-1295 dosage in units on an insulin syringe?

Divide total peptide (mcg) by mL of bacteriostatic water added to get concentration (mcg/mL). Divide your target dose by that concentration to get mL, then multiply by 100 for units on a U-100 syringe. Example: a 2,000 mcg vial in 2 mL water is 1,000 mcg/mL; a 100 mcg dose is 0.1 mL, or 10 units.

What is a typical CJC-1295 dose in mcg?

Published pharmacokinetic studies used roughly 1-2 mcg/kg per dose. Popular self-directed protocols use flat doses of 100-300 mcg, once or twice daily, for no-DAC CJC-1295. Neither range comes from a trial that tested outcomes across doses; both are starting points, not verified optimal doses.

What's the difference between CJC-1295 and CJC-1295 with DAC for dosing purposes?

No-DAC CJC-1295 has a half-life of tens of minutes and is dosed multiple times daily or before specific activities. CJC-1295 with DAC binds albumin and has a half-life of roughly 6-8 days, so it's dosed about once weekly. Using one compound's schedule with the other's dosing logic is a common, meaningful error.

Does body weight matter when calculating CJC-1295 dose?

Human pharmacology studies dosed on a mcg/kg basis (roughly 1-2 mcg/kg), which scales with body size. Most forum protocols use flat doses regardless of weight. Mcg/kg is more consistent with how the underlying studies were structured, though those studies were small and not designed to define an optimal dose.

Why is CJC-1295 combined with ipamorelin?

CJC-1295 acts on the GHRH receptor while ipamorelin acts on the ghrelin receptor, a different mechanism. The rationale is that combining two distinct GH-release pathways may produce a larger pulse than either alone, an idea with some support in older combined-secretagogue studies, though the specific pairing hasn't been validated in a large controlled human trial.

How much ipamorelin do you pair with a given CJC-1295 dose?

Ipamorelin is typically dosed independently, commonly 200-300 mcg per dose in informal protocols, and does not scale directly off the CJC-1295 dose. Calculate reconstitution and volume for each peptide separately, since they usually come in separate vials with different concentrations.

What happens if I miscalculate my CJC-1295 dose?

A math error usually happens at reconstitution, not dose selection. Getting the water-to-peptide ratio wrong can mean drawing far more or less volume than intended. Reported GH-axis-related effects include water retention, joint discomfort, and blood glucose changes; severe controlled-trial safety data at high doses doesn't exist, so conservative dosing is the safer default.

Is CJC-1295 FDA approved, and does that affect dosage guidance?

No. CJC-1295 has no FDA-approved indication and isn't in the FDA's approved drug database. Because of that, there's no manufacturer package insert or agency-reviewed dosing chart; all dosing guidance in circulation comes from small pharmacology studies or informal protocol-sharing, not regulatory review.

How often should CJC-1295 be injected?

No-DAC CJC-1295 is typically dosed once or twice daily, often before bed or before fasted training, because it clears within roughly an hour or two. CJC-1295 with DAC is typically dosed about once weekly because its half-life extends to roughly 6-8 days, keeping levels elevated between doses.

Can I use the same calculator for CJC-1295 and CJC-1295 with DAC?

The reconstitution and volume math (mcg per mL, dose divided by concentration) is identical for both. The dosing frequency and target mcg range are not: no-DAC uses smaller, more frequent doses, while DAC uses larger, once-weekly doses. Confirm which version you have before applying any frequency assumption.

Where can I find real research on CJC-1295 instead of forum dosing charts?

Start with the original pharmacology publication on the DAC modification and half-life extension, and check the FDA's approved drug database to confirm CJC-1295's regulatory status. Independent review articles on GH secretagogues in endocrinology journals are more reliable than forum threads, which aggregate anecdote rather than trial data.

Sources

1. U.S. Food & Drug Administration, Drugs@FDA database: CJC-1295 has no FDA-approved indication and does not appear in the FDA's approved drug database
2. Ionescu M, Frohman LA, Pharmacodynamics of GRF(1-29) analogue (CJC-1295 without DAC), Journal of Clinical Endocrinology & Metabolism: Human pharmacokinetic studies of CJC-1295-related GHRH analogues used mcg/kg dosing and documented a short circulating half-life
3. National Center for Biotechnology Information, PubMed entry on CJC-1295 GHRH analogue pharmacology: Published pharmacology data on GHRH analogue dosing exists separately from popular flat-dose self-administration protocols
4. Teichman SL et al., Prolonged stimulation of growth hormone by CJC-1295 (DAC:GRF), Journal of Clinical Endocrinology & Metabolism: CJC-1295 with DAC extends half-life to approximately 6 to 8 days via albumin binding
5. National Center for Biotechnology Information, PubMed entry on ipamorelin pharmacology: Ipamorelin acts as a selective ghrelin-receptor agonist distinct from GHRH-receptor mechanisms
6. Sigalos JT, Pastuszak AW, Growth hormone secretagogues review, Sexual Medicine Reviews: Combined GHRH-analogue and ghrelin-mimetic secretagogue use has documented rationale for augmented growth hormone release in some studies
7. National Center for Biotechnology Information, StatPearls, Growth Hormone Releasing Hormone Analogs: Reported effects of GH-axis stimulating peptides include water retention, injection site reactions, and glucose metabolism changes